Abstract: Assay devices are provided including a receptacle having a sample entry port; a plunger disposed within the receptacle; at least one reagent; a membrane attached to a first surface of the plunger; a wick providing capillary force; and a detection zone. The membrane includes a target conjugate zone in which affinity components are disposed. Capture compounds are immobilized in a detection zone, which is located between the target conjugate zone and the wick. A method of detecting a target analyte is also provided, including providing the assay device; providing a sample suspected to contain a target analyte; adding the sample onto the device; allowing the sample to travel along the membrane until the sample reaches the detection zone; immobilizing the target analyte through reaction of the target analyte with the capture compounds; reacting the immobilized target analyte with a reagent to generate a detectable signal; and detecting the generated signal.

Abstract: The present disclosure describes novel caninized anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further describes use of the novel antibodies, antigen binding proteins and/or nucleotides of the invention for the treatment and/or prevention of NGF related disorders, particularly for the management of canine pain.

Abstract: The invention provides novel caninized anti-NGF antibodies (such as caninized anti-NGF antagonist antibodies and antigen binding proteins), and polynucleotides encoding the same. The invention further provides use of said antibodies or antigen binding proteins and/or nucleotides in the treatment and/or prevention of NGF related disorders, particularly pain.

Abstract: Assay devices are provided including a receptacle having a sample entry port; a plunger disposed within the receptacle; at least one reagent; a membrane attached to a first surface of the plunger; a wick providing capillary force; and a detection zone. The membrane includes a target conjugate zone in which affinity components are disposed. Capture compounds are immobilized in a detection zone, which is located between the target conjugate zone and the wick. A method of detecting a target analyte is also provided, including providing the assay device; providing a sample suspected to contain a target analyte; adding the sample onto the device; allowing the sample to travel along the membrane until the sample reaches the detection zone; immobilizing the target analyte through reaction of the target analyte with the capture compounds; reacting the immobilized target analyte with a reagent to generate a detectable signal; and detecting the generated signal.

Abstract: Skin penetration enhancers comprising peptides are disclosed. Compositions comprising the skin penetration enhancers are also provided. The compositions further comprise an active agent, such as a pharmaceutically active agent, a vaccine, a cosmetic agent, and a. nutritional supplement. Methods of transdermal ly delivering a pharmaceutically active agent, a vaccine, a cosmetic agent, or a nutritional supplement are also provided.

Abstract: The present disclosure encompasses novel caninized anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotides of the invention for the treatment and/or prevention of NGF related disorders, particularly for the management of canine pain.

Abstract: A multi-element lens for controlling defocus and eye diopter for prevention and treatment of myopia and hyperopia. The multi-element lens includes one large unit convex lens for generating large defocus. One small unit concave lens for generating small defocus or focus through combination is combined on the lens of the large unit convex lens, or one small single lens is separately provided on the large unit convex lens. When an eye watches different distances through the lens, the central view region is in a small nearsightedness defocus or focus state, or a small farsightedness defocus or focus state, whereas the equatorial view region is always in a nearsightedness or farsightedness defocus state. Through the special influences of light on the view regions of human eyes, the growth of the ocular axis can be effectively controlled, which achieves the characteristics of good and fast prevention and treatment of myopia and hyperopia.

Abstract: Skin penetration enhancers comprising peptides are disclosed. Compositions comprising the skin penetration enhancers are also provided. The compositions further comprise an active agent, such as a pharmaceutically active agent, a vaccine, a cosmetic agent, and a. nutritional supplement. Methods of transdermal ly delivering a pharmaceutically active agent, a vaccine, a cosmetic agent, or a nutritional supplement are also provided.

Abstract: A multi-element lens for controlling defocus and eye diopter for prevention and treatment of myopia and hyperopia. The multi-element lens includes one large unit convex lens for generating large defocus. One small unit concave lens for generating small defocus or focus through combination is combined on the lens of the large unit convex lens, or one small single lens is separately provided on the large unit convex lens. When an eye watches different distances through the lens, the central view region is in a small nearsightedness defocus or focus state, or a small farsightedness defocus or focus state, whereas the equatorial view region is always in a nearsightedness or farsightedness defocus state. Through the special influences of light on the view regions of human eyes, the growth of the ocular axis can be effectively controlled, which achieves the characteristics of good and fast prevention and treatment of myopia and hyperopia.

Abstract: The invention provides novel caninized anti-NGF antibodies (such as caninized anti-NGF antagonist antibodies and antigen binding proteins), and polynucleotides encoding the same. The invention further provides use of said antibodies or antigen binding proteins and/or nucleotides in the treatment and/or prevention of NGF related disorders, particularly pain.

Abstract: A device for preventing and treating myopia includes a base, a spectacles frame (1), a holder (3) and a lens (2). The holder (3) is mounted on the base; a visual target (4) is placed on the base. The spectacles frame (1) is connected to the holder (3) by adjustable connecting parts (31,32,33,34,35), so the distance between the spectacles frame (1) and the visual target (4) which is placed on the base is adjustable.

Abstract: A device for preventing and treating myopia includes a base, a spectacles frame (1), a holder (3) and a lens (2). The holder (3) is mounted on the base; a visual target (4) is placed on the base. The spectacles frame (1) is connected to the holder (3) by adjustable connecting parts (31,32,33,34,35), so the distance between the spectacles frame (1) and the visual target (4) which is placed on the base is adjustable.